摘要
目的比较冻干重组人脑利钠肽(rhBNP)治疗急性失代偿性心力衰竭的疗效和安全性。方法28例急性失代偿心力衰竭患者随机分为两组,rhBNP组(n=15)以rhBNP1.5μg/kg静脉注射后,再以0.0075μg/kg连续滴注;对照组(硝普钠NIT,n=13)静脉持续泵入硝普钠。记录两组治疗前后呼吸困难程度和左室射血分数(LVEF)。rhBNP组安全性评估采用用药过程中及用药后定期测量血压、心率,并对过程中所有不良事件进行记录。结果治疗48h后rhBNP组呼吸困难和临床状况好转率优于对照组(P<0.05);rhBNP组治疗后左室收缩功能指数较对照组明显改善(P<0.05)。在与药物相关不良反应方面,两组差异无统计学意义(P>0.05)。结论重组人脑利钠肽能明显改善急性失代偿性心衰患者呼吸困难程度及全身临床状况,超声提示心脏收缩功能改善,其安全性与硝普钠相似。
Objective To compare the efficacy and safety of intravenous infusion recombinant human brain natriuretic peptide （rhBNP）in treating patients with decompensated acute heart failure. Methods 28 patients characterized of deeompensated acute heart failure were randomly allocated to rhBNP and nitroprusside（NIT）. Each group was respectively received rhBNP（ 1.5 μ g/kg bolus intravenous injection followed by 0.0075μ g/（ kg. min ）for 48 hours, n = 15 ）and NIT（starting at 10 μg/min and increasing 5 μg/min each time till clinical effective dose for 48 hours, n = 13）. Blood pressure,heant rate,dyspnea grade and improvement in patient sympotoms and signs were evaluated and adverse events were documented. Results Dyspnea and symptom improvements were more significant in rhBNP compared to NIT group.The totol adverse evernts were comparable between the two groups. Conclusion rhBNP is superior to nitroprusside in improving dyspnea and symptoms. The safety of rhBNP is comparable to nitroprusside in treating patients with decompensated acute heart failure.
出处
《中国现代医生》
2009年第15期92-93,共2页
China Modern Doctor
关键词
急性心力衰竭
重组人脑利钠肽
Acute heart failure
Recombinant human brain nitriuretic peptide
